The potential drugs show high efficacy and low toxicity
Read moreThis discovery not only advances understanding of the mechamisms underlying this disease; it could also support the development of new strategies to treat or even prevent the disease.
Read moreThe molecules synthesized by Ernest Giralt’s lab at IRB Barcelona bind a key protein in cancer that has received little attention as a therapeutic target. The long-term goal is to provide a new chem...
Read moreEl grupo de investigación NanoBioCel de la Universidad del País Vasco/Euskal Herriko Unibertsitatea ha desarrollado un sistema biomimético que busca diseñar y desarrollar medicamentos adaptados a ...
Read moreResearch has been conducted in animal models of several autoimmune diseases. By this approach glucose blood levels have been restored in mice with type 1 diabetes, motor function has been addressed in...
Read moreDescubren cómo una simple mutación podría convertir enzimas que hidrolizan carbohidratos en enzimas que los sintetizan Este hallazgo, que recoge la revista Journal of the American Chemical Society ...
Read moreResearchers at the Institute of Biotechnology and Biomedicine have published, in Nature Communications, the results of a drug repositioning study in which they describe a powerful drug that could sign...
Read moreThey create a promising platform of gene therapy projects with the addition of two new therapies for Sanfilippo B (EGT-201) and Hunter syndromes (EGT-301). These two new therapies join the leading pro...
Read moreSe trata de un nuevo cannabinoide semisintético que actuando sobre dos receptores que modula la respuesta inflamatoria y fibrótica, por una parte ejerce una actividad inhibidora del sistema inmune d...
Read moreThe proposal of the Centro Nacional de Biotecnología of CSIC and the University of Santiago de Compostela is one of the six winning projects of the Discovery Fast Track programme of the company GSK. ...
Read moreCancer stem cells (CSCs) contribute to disease progression and treatment failure in prostate cancer because of their intrinsic resistance to current therapies. The transcription factors NF-κB and STA...
Read moreTolcapone podría estar en el mercado en un plazo de cinco años. En un ensayo clínico preliminar (liderado por el Dr. Josep Gámez, Institut de Recerca del Hospital Universitari Vall d’Hebron, en ...
Read more